摘要
胃癌因其症状不特异，诊断晚，治疗效果不理想，为全球死亡率第二的恶性肿瘤。随着对胃癌分子生物学特性认识加深，针对特异性分子或基因的靶向药物逐步进入临床试验。本文回顾了相关靶向药物在胃癌的临床研究进展。
出处
《癌症进展》
2010年第5期466-470,共5页
Oncology Progress
参考文献25
-
1Iqbal S,Goldman B,Lenz HJ,et al.S0413:A phase Ⅱ SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer[J].J Clin Oncol,2007,25 (18Suppl):4621.
-
2Tebbutt NC,Sourjina T,Strickland AH,et al.ATFAX2:Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer--Final results of a multicentre phase Ⅱ trial by the AGITG[J].J Clin Oncol,2008,26 (15Suppl):15554.
-
3Lordick F,Lorenzen S,Hegewisch-Becker S,et al.Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer:Final results from a multicenter phase Ⅱ study of the AIO upper GI study group[J].J Clin Oncol,2007,25 (18_Suppl):4526.
-
4Pinto C,Di Fabio F,Siena S,et al.Phase Ⅱ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)[J].Ann oncol,2007,18 (3):510.
-
5Kim C,Lee JL,Ryu MH,et al.A prospective phase Ⅱ study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer[J].Invest New Drug,2009,Dec 9.[Epub ahead of print].
-
6Pinto C,Di Fabio F,Barone C,et al.Phase Ⅱ study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)[J].Br J Cancer,2009,101 (8):1261.
-
7Woell E,Greil R,Eisterer W,et al.Oxaliplatin,irinotecan,and cetuximab in advanced gastric cancer.First efficacy results of a multicenter phase Ⅱ trial (AGMT Gastric-2)of the Arbeitsgemeinschaft Medikamentoese Tumortherapie(AGMT)[J].J Clin Oncol,2009,27 (15S):4538.
-
8Han SW,Oh DY,Im SA,et al.Phase Ⅱ study and biomarker analysis of cetuximah combined with modified FOLFOX6 in advanced gastric cancer[J].Br J Cancer,2009,100(2):298.
-
9Xia L,Guo G,Zhang B,et al.Short-term efficacy of Cetuximab-contained regimen on patients with advanced gastrointestinal (noncolorectal) cancer:Experiences of 16 patients in single institute[J].Chinese-German J Clin Oncol,2009,8 (11):669.
-
10Van Cutsem E,Peeters M,Siena S,et al.Open-Label Phase Ⅲ Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer[J].J Clin Oncol,2007,25 (13):1658.
同被引文献18
-
1张大悦.FOLFOX4方案治疗晚期胃癌的临床观察[J].实用诊断与治疗杂志,2007,21(6):423-424. 被引量：2
-
2Unruh A,Ressel A,Mohamed HG,et al.The hypoxia inducible factor 1 alpha is a negative factor for tumor therapy[J].Oncogene,2003,22(21):3213-3220.
-
3Semenza GL.HIF 1 and tumor progression:pathophysiology and therapeutics[J].Trends Mol Med,2002,8:562-567.
-
4Semenza GL.Targeting HIF-1 for cancer therapy[J].Nat Rev Cancer,2003,3:721-732.
-
5Erler JT,Cawthorne CJ,Williams KJ,et al.Hypoxia mediated down regulation of Bid and Bax in tumors occurs via hypoxia inducible factor 1 dependent and independent mechanisms and contributes to drug resistance[J].Mol Cell Biol,2004,24:2875-2889.
-
6Goda N,Dozier SJ,Johnson RS.HIF-1 in cell cycle regulation,apoptosis,and tumor progression[J].Antioxid Redox Signal,2003,5:467-473.
-
7Yamakawa M,Liu LX,Date T,et al.Hypoxia inducible factor 1 mediates of cultured endothelial cells by inducing multiple angiogenic[J].Circ Res,2003,93(7):664-673.
-
8Han S W, Oh D Y, Im S A, et al. Phase Ⅱ study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer[J]. Br J Cancer,2009,100(2):298-304.
-
9Pinto C, Di Fabio F, Barone C, et al. Phase Ⅱ study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocareinoma (DOCETUX study)[J], Br J Cancer, 2009,101(8) : 1261- 1268.
-
10Sasaki T, Maeda Y, Kobayashi T, et al. Standard chemotherapy for gastrointestinal malignancies based on evidence[J].Gan To Kagaku Ryoho,2000,27(2) :166-176.
引证文献3
-
1梁磊,罗华友.缺氧诱导因子2与大肠癌的研究进展[J].医学信息（中旬刊）,2011,24(5):2013-2014.
-
2张桂芳,马晓艳,鲁一,慕竹青,周林静,孟娜娜,景海曼,齐路霞,李新.西妥昔单抗联合化疗治疗晚期胃癌疗效观察[J].中华实用诊断与治疗杂志,2011,25(6):587-588. 被引量：2
-
3周希,夏国栋,邓明明.人端粒酶逆转录酶下调p53促进胃癌细胞抵抗氧化应激下的死亡[J].西南医科大学学报,2017,40(5):429-433.
二级引证文献2
-
1高玲,张红梅,徐晗.西妥昔单抗联合化疗应用于消化系统肿瘤患者的效果评价[J].中国实用护理杂志,2012,28(24):67-68. 被引量：2
-
2王玉峰,王新帅,高社干,单探幽,冯笑山.表皮生长因子受体在食管癌中的表达及临床意义[J].中华实用诊断与治疗杂志,2012,26(9):868-870. 被引量：3
-
1秦翠云,强荣,高俊萍.结肠癌相关基因研究进展[J].第四军医大学学报,2008,29(23):2204-2205. 被引量：2
-
2周洪益,周志毅,邵剑锋,胡强,王志荣,王强,单玉喜,徐卓群.内皮特异性分子1表达与膀胱尿路上皮癌临床病理的关系[J].中华实验外科杂志,2015,32(6):1233-1235. 被引量：2
-
3汪颖(综述),王宁(综述),王雅杰(审校).三阴乳腺癌潜在治疗靶点[J].国际肿瘤学杂志,2009,36(8):593-596.
-
4李静文,周琦,左慧萍.ESM-1在子宫内膜癌组织中表达及临床意义[J].临床和实验医学杂志,2014,13(4):306-309. 被引量：3
-
5杜红延,王捷,郭勇.乳腺癌骨转移的特异性分子机制研究[J].广东医学,2004,25(12):1469-1471. 被引量：3
-
6全姬善,唐佳松.子宫内膜癌患者癌组织中ESM-1和β-arrestin-2蛋白的表达[J].中国妇幼保健,2016,31(9):1973-1974.
-
7周锋,倪启超,张春辉.乳腺癌骨转移的特异性分子机制研究进展[J].内分泌外科杂志,2008,2(3):202-204. 被引量：2
-
8杨松梅,李晓颖,段庆华.Notchl和P27在大肠腺癌中的表达及其意义[J].中国保健营养（临床医学学刊）,2010,19(7):169-170.
-
9段伊帆,李子俊.消化系肿瘤的分子靶向治疗研究进展[J].国际消化病杂志,2012,32(2):110-113.
-
10柳江,王芳.胰腺癌的分子靶向治疗[J].肿瘤预防与治疗,2009,22(4):435-438. 被引量：1
